Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law In 2023, the FDA deemed 19 peptides too unsafe to be dispensed by compounding pharmacies. Now, under RFK Jr., the agency is poised to reverse itself despite the fact that few Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Compounded "semaglutide" is not FDA approved semaglutide.com The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and